Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.

Pediatric pulmonology - 1 Feb 2022

Ragan Hunter, Autry Elizabeth, Bomersback Taryn, Hewlett Jennifer, Kormelink Lauren, Safirstein Julie, Shanley Laura, Lubsch Lisa

Abstract excerpt

INTRODUCTION: Cystic fibrosis (CF)-related liver disease (CFLD) manifests as a wide spectrum of hepatobiliary disease and can progress to need liver transplantation. Elexacaftor/tezacaftor/ivacaftor (elx/tez/iva) is a cystic fibrosis transmembrane conductance regulator modulator that has superior efficacy compared to previously approved modulators. Use of elx/tez/iva, should be approached with caution in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Drug Combinations

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 34850610
DOI: 10.1002/ppul.25779

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.PMID 34850610Read ↗

Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant.Semantic proximity Read ↗

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.Semantic proximity Read ↗

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 3: Solid organ transplant.Semantic proximity Read ↗

Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.Semantic proximity Read ↗

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.Semantic proximity Read ↗

The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France.Semantic proximity Read ↗

ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.Semantic proximity Read ↗

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.